Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

This case report describes how changing treatment from adalimumab to guselkumab successfully controlled both pustulotic arthro-osteitis and paradoxical skin reactions in a patient with palmoplantar pustulosis.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.

A medication may help with hair growth in psoriasis, and a skin condition might be linked to a specific bacteria.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

This review discusses recent advances in how proinflammatory cytokines affect epidermal stem cell function during skin wound healing and introduces potential therapies targeting these cells and cytokines.

This study reports a case of complete hair regrowth in lichen planopilaris after 12 weeks of treatment with ixekizumab, suggesting its potential as a targeted therapy.

This study found that blocking interleukin-3 improved lupus nephritis symptoms in MRL/Ipr mice, suggesting IL-3 may play a role in the disease's progression.

This study found that in a mouse model of Ross River virus-induced joint inflammation, targeting IL-17A and IL-17A/F heterodimers reduced disease severity.

In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.

This paper discusses the evolving understanding of psoriasis pathogenesis with no new clinical findings; the authors highlight the role of T-cell plasticity and regulatory cells, calling for further clinical applications using single-cell technologies.

This review highlights ongoing efforts in drug repurposing and development of new therapeutics against COVID-19, emphasizing the promise of these strategies in addressing the challenges posed by SARS-CoV-2 mutations and post-infection complications.

This article discusses adverse immune-mediated skin reactions associated with TNF-alpha inhibitors, highlighting paradoxical reactions such as psoriasis that occur despite being treated with medications intended to alleviate the condition.

This review discusses recent advances in understanding the pathogenesis of autoimmune alopecia areata and reports no new clinical results; it highlights potential for developing more effective treatments.

This study found that type 2 immunity, especially involving ILC2 cells, helps maintain skin homeostasis by regulating the proliferation and community stability of hair follicle epithelial cells in the presence of Demodex mites.

This report reviews peer-reviewed case studies indicating potential efficacy of ustekinumab for treating challenging forms of psoriasis but notes the need for further research on cost-effectiveness and risk-benefit.

This review discusses the mechanisms of hair repigmentation and reports no clinical results; the authors suggest further research into topical treatments for reversing gray hair.

OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.

This review highlights the application of microneedle technology as a promising advancement in psoriasis management, focusing on its roles in enhanced transdermal drug delivery and minimally invasive biomarker monitoring, while also discussing current challenges and future research directions.

This study found that feeding aged mice a probiotic yogurt induced changes leading to thicker, healthier fur, suggesting a bacteria-triggered interleukin-10-dependent mechanism that mimics signs of youth and reproductive fitness.

This article reviews the role of perifollicular regulatory T cells in maintaining hair follicle integrity in the context of hidradenitis suppurativa and calls attention to inflammatory mechanisms without reporting new clinical results.

This review explores the role of Tregs in autoimmune skin diseases, transplantation, and skin cancer, and discusses Tregs-based therapies' potential for treating autoimmunity without reporting new experimental results.

This study found that feeding mice a high-fat diet with fish oil leads to hair loss through a mechanism involving omega-3 fatty acids and TNF-α signaling, with epidermal fatty acid binding protein playing a key role.

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

This proof-of-concept study reported that a new, ultra-fast, one-step immunohistochemistry method improved the interpretation of Mohs surgery slides, particularly for poorly differentiated tumors.

New acne treatments show promise as alternatives to traditional therapies.

In this study, researchers found that the cell surface protein Lrig1 plays a crucial role in regulating the suppressive function of regulatory T cells, suggesting it as a potential target for treating autoimmune diseases, as evidenced by experiments in mouse models.